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ABSTRACT
Small cell lung cancer usually responds to radiation and chemotherapy, but cures are infrequent. Autotransplan-
tation attempts to increase cures by intensifying the effects of chemotherapy. We studied 103 patients receiving
high-dose chemotherapy with autologous hematopoietic stem cell transplantation (SCT) for small cell lung can-
cer in 1989-1997 at 22 centers participating in the Autologous Blood and Marrow Transplant Registry. Median
age at transplantation was 50 years (range, 30-74 years). Fifty-five percent of patients were men. Forty-seven
percent of patients underwent transplantation in 1989-1993 and 53% in 1994-1997. Most patients received
peripheral blood stem cells alone (39%) or with bone marrow (44%); 18% received bone marrow alone. The
2 most common preparative regimens were cyclophosphamide/carmustine/cisplatin (CBP) (60%) and ifos-
famide/carboplatin/etoposide (ICE) (28%). Median time from diagnosis to transplantation was 6 months (range,
1-34 months). Most patients underwent transplantation after partial response (66%) or complete response
(27%) to combination therapy. The 100-day mortality was 11% (95% confidence interval [CI], 6%-18%). Three-
year probabilities of survival and progression-free survival (PFS) were 33% (95% CI, 24%-44%) and 26% (95%
CI, 17%-36%), respectively, for all patients. Factors negatively associated with outcome in multivariate analysis
were age greater than 50 years, extensive-stage disease at presentation, and preparative regimens other than
CBP or ICE. Three-year survival and PFS rates were higher in patients with limited versus extensive disease,
43% versus 10% (P < .001) and 35% versus 4% (P < .001), respectively. Patients older than 50 years had nearly
twice the risk of death or progression as younger patients (relative risk, 1.7; 95% CI, 1.1-2.8). Autologous SCT
produces long-term survival in some patients with small cell lung cancer; SCT outcomes appear better in young
patients with limited-stage disease. Transplantation for patients with extensive disease does not appear to pro-
duce substantial benefit.
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INTRODUCTION
In the United States, cancer is the second most common
cause of death, and lung cancer is the leading cause of can-
cer death in men and women [1]. About 164,000 new cases
of lung cancer were diagnosed in 2000. Fifteen percent to
25% of lung cancers are histologically small cell [1,2]. The
distinction between small cell lung cancer (SCLC) and
non–small cell lung cancer is important, because small cell
tumors are more sensitive to chemotherapy. For patients
with limited-stage SCLC (30%-40% of patients), deﬁned as
disease that is conﬁned to 1 hemithorax and can be encom-
passed within a single radiation therapy port, the mainstay
of treatment is chemotherapy and radiation [3]. Median sur-
vival after chemotherapy and radiation for patients with limited-
stage SCLC is 18 to 24 months, with fewer than 25% of
patients surviving longer than 5 years [3-6]. For patients
with extensive disease, median survival is less than 9 months,
with rare survivors beyond 5 years [4].
Because SCLC is sensitive to chemotherapy, attempts to
improve treatment outcome have included using high-dose
chemotherapy followed by stem cell support. The contribu-
tion of chemotherapy dose intensity to response and survival
remains controversial. Seven randomized trials have evalu-
ated dose intensity in SCLC, mostly in the extensive-stage
setting [7-13]. Dose intensity of the high-dose arms varied
from 1.2 to 2-fold that of the lower-dose arms. Statistically
signiﬁcant increases in response and survival were observed
for the higher-dose arms, although the clinical beneﬁt was
modest. In the only randomized trial exclusively treating
patients with limited-stage SCLC, Arriagada et al. [13] used
6 cycles of chemotherapy in which the ﬁrst cycle was either
standard dose or modestly intensified. Intensification (not
requiring transplantation) resulted in a complete response
(CR) and survival advantage. In the only randomized trial of
high-dose therapy with autotransplantation, Humblet et al.
[14] treated 101 SCLC patients with chemotherapy for
5 cycles without thoracic radiotherapy. Forty-five patients
were eligible for randomization to 1 further cycle of either
high-dose or conventional-dose therapy with cyclophos-
phamide, etoposide, and carmustine [14]. A clear dose-
response effect was demonstrated. Conversion from partial
response (PR) to CR occurred in about 77% of patients after
high-dose therapy compared with none after conventional-
dose treatment. The disease-free survival rate was signiﬁcantly
higher in the high-dose arm, with a trend toward improved
survival. However, an 18% toxic death rate on the high-dose
arm led the investigators to conclude that high-dose therapy
should not be considered a standard therapy for SCLC. More-
over, chest radiotherapy was not given in this trial, and almost
all patients who relapsed had disease recurrence in the chest.
More recent studies suggest that survival and disease-free
survival rates after autotransplantation for SCLC have
improved with better initial treatment at diagnosis and better
supportive care posttransplantation. In the Dana-Farber
Cancer Institute/Beth Israel Hospital experience, the 5-year
disease-free survival rate for selected patients with limited-
stage disease in CR or near-CR at the time of high-dose
therapy was 52% (median follow-up period, 61 months) [15-
17]. This evaluation of patients receiving autotransplantation
for SCLC reported to the Autologous Blood and Marrow
Transplant Registry (ABMTR) was undertaken to identify
patients most likely to beneﬁt from high-dose therapy and to
evaluate the most commonly used transplantation strategies.
MATERIALS AND METHODS
Autologous Blood and Marrow Transplant Registry
The ABMTR is a voluntary organization of more than
200 institutions that perform autotransplantations, primarily
in the United States, Canada, and Central and South Amer-
ica. Centers report data on consecutive autotransplantations
to a Statistical Center at the Medical College of Wisconsin.
Data Collection
The ABMTR began data collection in 1992. Data were
collected retrospectively for patients who received auto-
transplants between 1989 and 1992 and prospectively
thereafter. Participating centers register consecutive auto-
transplantations for all disease indications. Based on data
collected in a recently conducted survey of all US trans-
plantation centers, 50% to 60% of autotransplantations in
North America are registered with the ABMTR [18].
The ABMTR collects data at 2 levels: registration and
research. Registration data include disease type, age, sex, pre-
transplantation disease stage and chemotherapy responsive-
ness, date of diagnosis, graft type (bone marrow and/or
blood-derived stem cells), high-dose conditioning regimen,
posttransplantation disease progression and survival, develop-
ment of a new malignancy, and cause of death. Requests for
data on progression or death for registered patients are made
at 6-month intervals. All ABMTR teams contribute registra-
tion data. Research data are collected on subsets of registered
patients, including comprehensive pre- and posttransplanta-
tion clinical information such as tumor size and pathology,
sites of disease, smoking status, all cancer treatments before
and after transplantation, clinical status (including cardiac,
pulmonary, renal, and liver function) before and after trans-
plantation, doses of high-dose therapy, blood or marrow graft
treatment, and sites of posttransplantation progression.
Patients
Thirty-nine teams registered 132 patients with SCLC
who received autotransplants between January 1, 1989, and
December 31, 1997. This analysis includes the 103 patients in
22 teams for whom research data were available (see above).
Participating centers are listed in the “Acknowledgments.”
Comparison of the 103 patients with research data to the
29 patients with only registration data showed the 2 groups to
be similar in age, sex, race, disease status at transplantation
(eg, CR, PR), year of transplantation, and interval from diag-
nosis to transplantation. Registration-only patients were less
likely to have received stem cells from both blood and bone
marrow than were the patients included in the study (12%
versus 39%, P = .04). Limited-stage disease was deﬁned as
tumor conﬁned to 1 hemithorax and regional lymph nodes
(including hilar, ipsilateral and contralateral mediastinal, and
ipsilateral and contralateral supraclavicular lymph nodes) and
ipsilateral pleural effusions (whether or not they were cyto-
logically positive). Extensive-stage disease was deﬁned as any
level of disease not meeting the deﬁnition of limited-stage
disease. CR was deﬁned as no evidence of residual tumor at
the primary or metastatic sites. PR was deﬁned as a decrease
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in size by 50% or greater at all measurable disease sites.
Patients experiencing a reduction in primary tumor size by
90% to 99% with either no metastatic tumor (scar may be
present) or mediastinal nodes less than 1.5 cm were consid-
ered to be very good partial responders (VGPR).
Statistical Methods
The primary outcomes were overall survival and pro-
gression-free survival (PFS) calculated from the day of
transplantation. Events were death, progression, and, for
patients with CR, recurrence of lung cancer. Individuals
alive without progression or recurrence were censored at
last follow-up. Univariate probabilities of survival, PFS, and
100-day mortality (death from any cause in the ﬁrst 100 days
after transplantation) were calculated using the Kaplan-
Meier product-limit estimator [19,20]. Variables were tested
in univariate analysis for their association with death and
treatment failure (the inverse of PFS) using Cox propor-
tional hazards regression [21]. Variables considered were age
(above or below the median), sex, Karnofsky performance
status at transplantation (<90% versus ≥90%), weight loss
(<5% versus ≥5%), smoking history, lactate dehydrogenase
(LDH) elevation at presentation, stage of disease at presen-
tation (limited versus extensive), number of chemotherapy
regimens, whether or not pretransplantation chemotherapy
contained platinum, number of chemotherapy cycles, best
response to initial chemotherapy, disease status at transplanta-
tion, pretransplantation thoracic radiation, pretransplantation
cranial radiation, interval from diagnosis to transplantation,
conditioning regimen, source of stem cells, year of trans-
plantation, and use of growth factors to enhance recovery.
For the ﬁnal multivariate model, forward stepwise selection
was used to select variables; a P value less than .05 was con-
sidered statistically significant. First-order interactions of
variables in the ﬁnal model were also checked. Using a time-
dependent covariate approach, we checked all variables to
ensure that the assumption of the Cox model was valid. A
score test [22] was used to determine whether any center-
speciﬁc effects required adjustment.
Planned Radiation after Transplantation. Studying effects
of posttransplantation maneuvers on outcome, such as post-
transplantation radiation therapy, must account for bias
introduced by early deaths occurring before intended treat-
ments were administered; ie, patients who die before
planned radiation treatments can be administered would be
considered in the no-treatment group even though such
treatment was planned. This bias artificially increases the
proportion of adverse events in the no-treatment group if all
patients are considered from the time of transplantation.
This bias was overcome by studying effects of posttransplan-
tation cranial and thoracic radiation therapy only in patients
already surviving more than 100 days after transplantation.
RESULTS
Patient characteristics are shown in Table 1. The
median age at transplantation was 50 years, and 55% of the
patients were men. Seventy-three percent of the patients
had limited-stage disease at diagnosis, a rate that is some-
what higher than would be expected in an unselected popu-
lation of SCLC patients. Only 21% of patients had more
than 20 pack-years of smoking history; 14% continued to
smoke after diagnosis. More than 90% of patients under-
went initial chemotherapy management with a platinum-
based regimen, with 54% of patients receiving 4 or fewer
cycles of chemotherapy pretransplantation. Seventy-nine
percent of patients experienced either a VGPR (50%) or CR
(29%) to their initial chemotherapy regimen. Fifty-ﬁve per-
cent of patients received thoracic radiation, and 6% received
cranial radiation before transplantation. Only 7% of patients
experienced relapse pretransplantation. Ninety-four patients
(93%) underwent autologous transplantation as part of their
initial management of SCLC. Median time from diagnosis
to transplantation was 6 months (range, 4-34 months). Only
3 patients had an interval from diagnosis to transplantation
greater than 1 year. Each had experienced a pretransplanta-
tion relapse after an initial response.
The most common high-dose regimens were cyclophos-
phamide, carmustine, and cisplatin (CBP) (60%) or ifos-
famide, carboplatin, and etoposide (ICE) (28%). Bone
marrow was the sole stem cell source in 18% of patients,
and blood was the sole source in 39%. Forty-four percent of
patients received both blood and bone marrow stem cells.
Growth factors were used to promote hematopoietic recov-
ery in 81% of patients. Planned posttransplantation thoracic
radiation was delivered to 33% of the patients, whereas
planned posttransplantation cranial irradiation was given to
64% of patients.
Median time to neutrophil recovery (0.5 × 109 cells/L)
was 11 days (range, 7-47 days). The probability of death
within 100 days was 11% (95% confidence interval [CI],
6%-18%) for the entire group. Causes of death within
100 days were toxicity (n = 5), recurrence (n = 2), infection
(n = 2), hemorrhage (n = 1), and interstitial pneumonitis
(n = 1). Among the 50 patients who died 100 days or
longer after transplantation, the primary causes of death
were progressive disease (n = 43), myocardial infarction
(n = 1), and not specified (n = 6). The 3-year probability of
PFS was 26% (95% CI, 17%-36%). Whereas 14 (30%) of
46 patients with VGPR to pretransplantation therapy con-
verted to CR with transplantation, no patient with PR had
a CR with transplantation.
The median time to relapse or progression was
18.6 months (95% CI, 11 to >36 months) for patients with
limited disease and 8.6 months (95% CI, 5-11 months) for
patients with extensive disease. The median survival and PFS
rates for patients with limited-stage disease were 23.5 months
(95% CI, 14.5-80 months) and 13.8 months (95% CI,
10.4-30 months), respectively.
Patients with limited-stage disease had 3-year probabili-
ties of survival and PFS of 43% (95% CI, 31%-54%) and
35% (95% CI, 23%-47%), respectively. Corresponding
probabilities for patients with extensive disease were 10%
(95% CI, 13%-45%) (Table 2, Figure 1) and 4% (95% CI,
1%-16%) (Table 2, Figure 2).
Table 3 shows the results of multivariate analyses of fac-
tors associated with overall survival and PFS. Extensive-
stage disease at presentation and age greater than 50 years
were signiﬁcant adverse prognostic factors for both overall
survival and PFS. High-dose chemotherapy with either CBP
or ICE conferred a similar prognosis. Once these factors
were considered in the multivariate models, primary tumor
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size, best response to initial chemotherapy, and radiation
therapy pretransplantation or posttransplantation (cranial or
thoracic) were not signiﬁcantly associated with overall sur-
vival or PFS. Table 2 shows the 3-year probabilities of overall
survival and PFS according to prognostic factors identiﬁed in
the multivariate analysis.
DISCUSSION
SCLC is known to be sensitive to several chemothera-
peutic agents, with a high rate of initial response. However,
despite initial response, about 40% to 47% of patients with
limited-stage disease and fewer than 5% of patients with
extensive-stage disease at presentation survive longer than
2 years [3-6]. Relapse-related mortality continues to occur
beyond 2 years. Consolidation of early responses with high
doses of chemotherapy followed by autologous hemato-
poietic stem cell rescue has been performed with the intent
to decrease this high recurrence rate.
Multiple previous small phase I and II studies of autolo-
gous transplantation for SCLC have been reported [23-30].
Results in patients undergoing transplantation for refractory
or recurrent disease have been dismal. When given as initial
therapy for SCLC, results have been no better than those
reported with conventional chemotherapy alone. However,
autologous transplantation used as intensification for
patients responding to first-line chemotherapy has shown
Table 1. Patient, Disease, and Transplantation Characteristics of 103
Patients with SCLC Reported to the ABMTR between 1989 and 1997 by
22 Teams Worldwide
Variable No. (%)
No. of patients 103
No. of reporting centers 22
Year of transplantation
1989-1991 18 (18)
1992-1994 41 (39)
1995-1997 44 (43)
Age at transplantation, median (range), y 50 (30-66)
Sex
Male 57 (55)
Female 46 (45)
Smoking history
≤20 packs/y 81 (79)
>20 packs/y 22 (21)
Performance score pretransplantation
90%-100% 62 (60)
<90% 39 (38)
Stage
Limited 75 (73)
Extensive 28 (27)
Histology
Small cell 97 (94)
Mixed small/non–small cell 6 ( 6)
Tumor stage
Tis 2 (2)
T1 12 (13)
T2 28 (30)
T3 22 (23)
T4 31 (32)
Lymph node stage
None 6 (6)
N1 5 (5)
N2 40 (42)
N3 44 (46)
LDH at presentation
Normal 79 (77)
Elevated 24 (23)
Surgery included in initial management
No 101 (99)
Yes 1 (1)
Chemotherapy as initial management
Platinum-based 94 (91)
Non–platinum-containing 9 ( 9)
No. of cycles chemotherapy pretransplantation
≤4 cycles 55 (54)
5 or more cycles 48 (47)
No. of chemotherapy regimens
1 88 (85)
2 or more 15 (15)
Best response to initial regimen
CR 29 (29)
VGPR (90%-99% decrease) 50 (50)
PR 19 (19)
Stable disease 2 ( 2)
Initial thoracic radiotherapy
Yes 56 (55)
No 46 (45)
Initial cranial irradiation
Yes 6 ( 6)
No 95 (94)
Continued
Table 1. Continued
Any relapse pretransplantation
Yes 7 ( 7)
No 94 (93)
Disease status at conditioning
CR 28 (27)
VGPR 49 (48)
PR 19 (18)
Stable disease 2 ( 2)
Progressive disease 5 ( 5)
Conditioning regimen
Cyclophosphamide/carmustine/cisplatin 62 (60)
Ifosfamide/carboplatin/etoposide 29 (28)
Other* 12 (12)
Graft type
Bone marrow 18 (18)
Peripheral blood stem cells 40 (39)
Bone marrow + peripheral blood stem cells 45 (44)
Interval from diagnosis to transplantation, 6 (4-34)
median (range), mo
Growth factors for recovery
Yes 83 (81)
No 20 (19)
Follow-up of survivors, median (range), mo 40 (3-96)
Planned radiation therapy after transplantation
Thoracic 14 (33)
Cranial 27 (64)
Other 1 ( 3)
*Carmustine (BCNU)/etoposide/thiotepa (n = 2); cyclophos-
phamide/BCNU/etoposide (n = 2); busulfan/thiotepa/melphalan (n = 1);
carboplatin/melphalan/etoposide (n = 1); cyclophosphamide/carbo-
platin (n = 1); cyclophosphamide/thiotepa (n = 1); and carboplatin ( n = 1).
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promise in some studies. Early case series, all small, sug-
gested no significant benefit of high-dose compared to
conventional chemotherapy. However, treatment-related
mortality during the period of those studies was higher than
the mortality expected with current supportive care tech-
niques. Humblet et al. reported a signiﬁcant improvement
in the disease-free survival rate for patients randomized to
autotransplantation compared to conventional therapy, but
this trial was flawed by a low randomization rate, small
numbers of patients, and high treatment-related mortality
(18%) [14]. Moreover, patients in the transplantation arm
did not have an improvement in overall survival.
More recent trials of autotransplantation for patients
with extensive disease provide little encouragement. Jennis
et al. reported a small trial of 10 patients with extensive-
stage disease at transplantation; all patients relapsed at a
median time of 4 months [31]. Likewise, patients with
extensive disease treated by Tomeczko et al. and Elias had
high rates of relapse [32,33]. Not surprisingly, patients with
limited-stage disease appear to have better disease-free and
overall survival rates than those receiving transplants for
extensive disease. Studies by Elias et al., Tomeczko et al.,
and Brugger et al. all report high response rates, with 2- or
3-year disease-free survival rates of 25% to 57% in patients
with limited-stage disease [17,32,34].
Few patients receive autologous transplantation for
SCLC. Our series of 103 autotransplantations for SCLC at
multiple centers represents a substantial proportion of the
procedures performed in the United States from 1989 to
1997. Our results indicate that for patients with limited-
stage disease, the 3-year probabilities of overall survival and
PFS were 43% and 35%, respectively. Although this is not a
comparative study, the 3-year survival results from auto-
transplantation are similar to the 2-year survival results
reported in large trials of chemotherapy/radiotherapy alone
for limited-stage disease [3-6,35]. However, the median sur-
vival and PFS in our patients are only slightly longer than
those reported in the same large trials, 19 to 21 months for
overall survival and 12 months for PFS, and fall within the
reported confidence intervals for these medians [3,5,6].
Thus, consolidation with autologous transplantation may
offer a small improvement in long-term survival of some
patients with limited-stage disease based on 3-year survival
probabilities. However, longer follow-up of this cohort of
transplantation patients is required to determine whether
patients receiving stem cell transplantation for limited-stage
disease experience lower late-failure rates than do patients
receiving conventional therapy.
Unfortunately, our ﬁndings conﬁrm that the prognosis
after autotransplantation for patients with extensive-stage
disease remains dismal, with 3-year probabilities of overall
survival and PFS of 10% and 4%, respectively.
Reported adverse prognostic factors for patients with
SCLC treated with chemotherapy alone include poor perfor-
mance score, male sex, and extensive-stage disease [36-38].
Our study found that adverse prognostic factors for PFS and
survival after autologous transplantation include age greater
than 50 years and extensive-stage disease. The 2 most
Table 2. Probability of Survival and Progression-Free Survival in Selected Groups
No. of Patients 3-Year Probability 3-Year Probability
Variable Evaluable of Survival (95% CI) P of PFS (95% CI) P
Stage of disease at presentation <.001 <.001
Extensive 28 10 (2-25) 4 (1-16)
Limited 75 43 (31-54) 35 (23-47)
Age at transplantation .04 .18
≥50 y 54 22 (10-37) 22 (11-35)
<50 y 49 46 (32-59) 30 (17-44)
Figure 1. Probability of survival by extent of disease.
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commonly used high-dose chemotherapy regimens, CBP and
ICE, appear to produce similar results. Although patients
receiving regimens other than CBP or ICE had a worse prog-
nosis in our models, the small number of patients receiving
different regimens makes it impossible to conclude that one
or more of them may not be equal or better than ICE or
CBP. Likewise, because the number of patients in the overall
study is small, it is possible that a small difference between
ICE and CBP exists but was not detected. Although response
to induction chemotherapy was previously reported to signiﬁ-
cantly predict outcome for patients with limited-stage disease
[17], we could not reproduce that ﬁnding in this study.
One limitation of this study is potential selection bias.
As an observational database of transplant recipients, the
ABMTR has no way of knowing which patients with limited
or extensive disease were evaluated by participating trans-
plantation centers but not considered to be reasonable
transplantation candidates. Secondly, 68 patients analyzed in
this study received their transplant at a single center.
Although it is possible that our results are driven by the
experience of a single center, statistical tests suggest that
there was no effect of transplantation center on the main
outcomes of the study.
Although the results of this analysis suggest that stem
cell transplantation for patients with limited-stage disease
offers minimal improvement in overall survival rate, only a
randomized clinical trial can appropriately answer the ques-
tion of whether autologous transplantation is superior to
conventional treatment regimens. Furthermore, a trial
directly comparing conventional chemotherapy/radiother-
apy with autologous stem cell transplantation would be ideal
to compare toxicities of therapy. It is conceivable that stem
cell transplantation offers similar or slightly improved sur-
vival with similar toxicity to combined modality conven-
tional therapy, which is associated with as much as 7% risk
of fatal pneumonitis [6] and substantial esophageal and pul-
monary toxicity [3,6].
Large database studies can help identify optimal patient
groups that should be investigated further in clinical trials. In
our study, limited-stage disease, age less than 50 years, and
high-dose therapy with either CBP or ICE were found to be
signiﬁcant predictors of survival and PFS after transplanta-
tion for SCLC. We conclude that patients with limited-stage
disease who are younger than 50 years should be studied in a
randomized trial that compares best conventional therapy
with transplantation after induction therapy. Ideally, such a
phase III trial would also include toxicity and quality-of-life
endpoints in addition to the usual outcomes of response and
PFS. In this way, the ﬁeld can move beyond pilot studies to
deﬁnitively address the role of dose intensiﬁcation.
Table 3. Factors Signiﬁcantly Associated with Survival or Progression-Free Survival in Multivariate Analyses
No. of Patients Relative Risk for Relative Risk for Progression
Variable Evaluable Death (95% CI) P or Death (95% CI) P
Stage of disease at presentation
Extensive 28 1.0 1.0
Limited 75 0.37 (0.20-0.68) .001 0.36 (0.21-0.64) <.001
Age at transplantation
≥50 y 54 1.0 1.0
<50 y 49 0.47 (0.28-0.78) .004 0.58 (0.36-0.94) 0.03
Preparative regimen .01* .002*
CBP 62 1.0 1.0
ICE 29 1.34 (0.70-2.53) .37 1.70 (0.95-3.04) .07
Others 12 3.42 (1.54-7.60) .003 3.82 (1.78-8.19) <.001
*Wald 2 degree of freedom test for overall signiﬁcance of variable.
Figure 2. Probability of progression-free survival by extent of disease.
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One randomized trial comparing conventional chemo-
therapy with high-dose chemotherapy for SCLC is under-
way in Europe [39]. This trial will compare patients with
either limited or extensive disease treated with conven-
tional-dose ICE to those treated with 2 cycles of epiru-
bicin/paclitaxel followed by 3 courses of high-dose ICE with
stem cell support. All patients in CR will receive posttrans-
plantation thoracic irradiation and prophylactic cranial irra-
diation. Researchers conducting this study hope to accrue
430 patients over 3 years.
A limitation to completion of clinical trials for SCLC,
however, may be the rate of accrual to the high-dose arm
following conventional induction. In a recent observational
study reported by Fetscher et al., only 58% of enrolled
patients with limited disease completed standard and high-
dose chemotherapy [40].
Although it is hoped that the results of a randomized
trial will establish more clearly whether SCT has a role in
the treatment of SCLC, especially for patients with limited-
stage disease, overall results have been disappointing.
Innovative approaches are required in the management of
this disease, particularly for patients who present with
extensive-stage disease.
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